November Nearly Doubled This Biotech's Shares

November saw Celsion (CLSN +3.31%) shares climb 71%, putting the stock at a year-to-date total of a 360% gain. The company is advancing its ThermoDox process through phase 3 trials for liver cancer. The process uses heat-sensitive nanoparticles that are then heated through RF ablation to kill tumors. More focus will be on this company in the near future as it moves closer to its phase 3 results, but as with any biotech stock with an upcoming binary event that could really drive share prices either way, the risk is inherently high; if the tests are a failure, the sell-off could be enormous.